Edition:
United Kingdom

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

25.42EUR
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
€25.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
697,134
52-wk High
€28.07
52-wk Low
€21.50

Latest Key Developments (Source: Significant Developments)

Grifols To Pay Gross Dividend Of 0.204 Euro per Share
Friday, 25 May 2018 

May 25 (Reuters) - Grifols SA ::TO PAY GROSS DIVIDEND OF 0.204 EUR PER SHARE AGAINST FY 2017.  Full Article

Grifols says FDA approves genetic test and EMA biological sealant
Friday, 17 Nov 2017 

Nov 17 (Reuters) - GRIFOLS SA ::GETS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS NEW GENETIC TEST TO DETECT ALPHA-1 ANTITRYPSIN DEFICIENCY‍​.THE EUROPEAN MEDICINES AGENCY (EMA) APPROVES NEW PRODUCT, BIOLOGICAL SEALANT, TO USE IN SURGICAL OPERATIONS IN ADULTS.‍​.  Full Article

Grifols gets approval from US FDA for new product
Monday, 6 Nov 2017 

Nov 6 (Reuters) - GRIFOLS SA ::EARNS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR NEW PRODUCT FIBRIN SEALANT (HUMAN) COMPOSED OF TWO PLASMA PROTEINS AND INDICATED FOR SURGICAL USE IN ADULTS.‍​.  Full Article

Grifols 9-month net profit up 6.3 pct at 431.8 mln euros YoY
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - GRIFOLS SA ::9-MONTH NET PROFIT 431.8 MILLION EUROS VERSUS 406.1 MILLION EUROS YEAR AGO.9-MONTH NET SALES 3.25 BILLION EUROS VERSUS 2.95 BILLION EUROS YEAR AGO.9-MONTH EBITDA 960.9 MILLION EUROS VERSUS 842.9 MILLION EUROS YEAR AGO.  Full Article

Grifols approves interim dividend of 0.18 eur/shr
Monday, 30 Oct 2017 

Oct 30 (Reuters) - GRIFOLS SA ::APPROVES INTERIM DIVIDEND OF 0.18 EURO PER SHARE PAYABLE DECEMBER 5‍​.  Full Article

Grifols says US prosecutor will not pursue case against Grifols
Friday, 7 Oct 2016 

Grifols SA :Says United States Department of Justice closes investigation on possible violations in Foreign Corrupt Practices Act against Grifols with declination to prosecute.  Full Article

Grifols' phase I Alzheimer vaccine study shows good safety profile, tolerability
Monday, 1 Aug 2016 

Grifols SA : Says unit Araclon Biotech presents phase I Alzheimer vaccine results showing good safety profile and tolerability . Says blind phase I study does not evaluate the effectiveness of treatment Further company coverage: [GRLS.MC] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Firday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: